Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ileah Reichert

Nurse Practitioner, Acute Care Columbus, OH Nurse Practitioner

NPI 1063783876 CMS profile 10926366

3535 Olentangy River Rd, Columbus, OH 43214

Open in the dashboard

General payments

$73,464

718 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ileah Reichert of Columbus, OH is reported in the CMS Open Payments database as having received $73,464 across 718 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,347 84
2024 General $18,306 169
2023 General $26,351 214
2022 General $16,426 170
2021 General $5,035 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ileah Reichert
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Ileah Reichert were reported at $7,347. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Ileah Reichert Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $5,035 $123 $38–$327 $132
2022 $16,426 $130 $44–$369 $149
2023 $26,351 $144 $49–$410 $160
2024 $18,306 $146 $48–$433 $164
2025 $7,347 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $55,304 557 payments
  2. Boston Scientific Corporation $6,801 66 payments
  3. Abbott Laboratories $4,461 41 payments
  4. E.R. Squibb & Sons, L.L.C. $3,907 19 payments
  5. Edwards Lifesciences Corporation $2,035 11 payments
  6. JenaValve Technology, Inc. $362 2 payments
  7. Janssen Scientific Affairs, LLC $121 1 payment
  8. AstraZeneca Pharmaceuticals LP $119 1 payment
  9. Janssen Pharmaceuticals, Inc $112 4 payments
  10. Pfizer Inc. $82 4 payments
  11. Other $161 12 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,031 27 payments
  2. Food and Beverage $21,844 591 payments
  3. Travel and Lodging $16,399 91 payments
  4. Consulting Fee $5,140 6 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,050 3 payments
Products named General payments · program years 2021–2025
  1. COREVALVE EVOLUT R $50,813 485 payments
  2. CoreValve Evolut $3,296 49 payments
  3. MITRACLIP Structural Heart $1,771 13 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $1,644 6 payments
  5. MitraClip System $670 9 payments
  6. PORTICO $656 10 payments
  7. GENERAL STRUCTURAL HEART $552 7 payments
  8. MITRACLIP Vascular $549 2 payments
  9. Avalus $420 13 payments
  10. JenaValve Pericardial TAVR System $362 2 payments
  11. Other $3,579 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

235

Median for Nurse Practitioner: 389

Drug cost

$279,230

Median for Nurse Practitioner: $21,885

Branded share of claims

67.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 28 $246,858
Xarelto Rivaroxaban Brand 16 $16,800
Eliquis Apixaban Brand 22 $14,362
Clopidogrel Clopidogrel Bisulfate Brand 75 $666
Metoprolol Succinate Generic 40 $331
Klor-Con M20 Potassium Chloride Brand 18 $132
Furosemide Generic 23 $59
Prednisone Generic 13 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$14,045

Medicare's payments for the services billed

Medicare patients

195

Average age 79

Services billed

227

81 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 70%
Atrial fibrillation 69%
Arthritis 66%
Diabetes 41%
Chronic kidney disease 40%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Scientific Affairs, LLC $121
$121 16 —
VYNDAQEL
  • PFIZER INC. $39
$39 — —
Wegovy
  • Novo Nordisk Inc $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record